

Editor

Leo van de Putte (The Netherlands)

Associate Editors

Thomas Bardin (France)
Johannes Bijlsma (The Netherlands)
Gerd Burmester (Germany)

Bevrah Hahn (USA)
Frank Wollheim (Sweden)
Anthony Woolf (UK)

Methodological Adviser

Jaap Fransen (The Netherlands)

Editorial Board

M Aringer (Austria)
P Bacon (UK)
F Berenbaum (France)
M Boers (The Netherlands)
D Boumpas (Greece)
B Bresnihan (Ireland)
H Capell (UK)
M Cutolo (Italy)
G Firestein (USA)
P Goupille (France)
E Gravalles (USA)
W Gross (Germany)
F Guillemin (France)
G Herrero-Beaumont (Spain)
F Houssiau (Belgium)
T Huizinga (The Netherlands)
C Jorgensen (France)
G Kollias (Greece)
T Kvien (Norway)
M Leirisalo-Repo (Finland)
F Luijten (Belgium)
H-M Lorenz (Germany)
W Maslinski (Poland)
M Maticci Cerinic (Italy)

K Nishioka (Japan)
M Nurmohamed (The Netherlands)
S Özen (Turkey)
T Pap (Germany)
E Pascual Gómez (Spain)
L Punzi (Italy)
L Rönblom (Sweden)
B Rozman (Slovenia)
G Schett (Austria)
J Da Silva (Portugal)
H Schulze-Koops (Germany)
A So (Switzerland)
T Sokka (USA)
D Symmons (UK)
P-P Tak (The Netherlands)
A Tyndall (Switzerland)
A Tzioufas (Greece)
J Vencovsky (Czech Republic)
M Ward (USA)
M Weisman (USA)
H Yazici (Turkey)
Editor, *BMJ*

Advisory Committee

W vd Berg (The Netherlands)
S Bombardieri (Italy)
F Breedveld (The Netherlands)
L Crofford (USA)
J-M Dayer (Switzerland)
M Doherty (UK)
M Dougados (France)
J Edmonds (Australia)
P Emery (UK)
D Furst (USA)
S Gay (Switzerland)
J Kalden (Germany)
E Keystone (Canada)
L Klareskog (Sweden)

P Lipsky (USA)
S Lohmander (Finland)
R Maini (UK)
E M Mola (Spain)
H Moutsopoulos (Greece)
J O'Dell (USA)
K Pavelka (Czech Republic)
J Rovinsky (Slovakia)
Y Shoenfeld (Israel)
J Smolen (Austria)
W van Venrooy (The Netherlands)
E Veys (Belgium)
A Wiik (Denmark)

Guidelines for Authors and Reviewers

Guidance for authors and reviewers can be found at <http://ard.bmj.com/ifaora>
All papers must be submitted via Bench>Press at <http://submit-ard.bmj.com>

Disclaimer

Annals of the Rheumatic Diseases is published by BMJ Publishing Group Ltd, a wholly owned subsidiary of the British Medical Association, and the European League Against Rheumatism.

The BMA grants editorial freedom to the Editor of the *Annals of the Rheumatic Diseases*. The *Annals of the Rheumatic Diseases* follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

The *Annals of the Rheumatic Diseases* is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions, the BMJ Publishing Group Ltd, The European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group Ltd shall not be liable for any loss, injury or damage resulting from the use of the *Annals of the Rheumatic Diseases* or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

Subscription Information

See p iv
ISSN 0003-4967 (print); 1468-2060 (online)


Copyright

© 2007 BMJ Publishing Group Ltd and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without the prior permission of *Annals of the Rheumatic Diseases*

• Authors are required to grant *Annals of the Rheumatic Diseases* an exclusive licence to publish; further details available online at <http://annrheumdis.com/ifaora/licence.dtl>

• *Annals of the Rheumatic Diseases* is published by BMJ Publishing Group, typeset by The Charlesworth Group, and printed in the UK on acid-free paper by Cambrian Printers Limited, Aberystwyth

• Periodicals postage paid, Rahway, NJ. Postmaster: send address changes to: *Annals of the Rheumatic Diseases*, c/o Mercury Airfreight International Ltd, 365 Blair Road, Avenel, NJ 07001, USA



Editorial

1409 Optimal use of methotrexate: the advantages of tight control *J W J Bijlsma, M E Weinblatt*

Review

1411 Cellular targets of interleukin-18 in rheumatoid arthritis *S-M Dai, Z-Z Shan, H Xu, K Nishioka*

Extended reports

1419 A novel gene variation of *TNF α* associated with ankylosing spondylitis: a reconfirmed study *X Zhu, Y Wang, L Sun, Y Song, F Sun, L Tang, Z Huo, J Li, Z Yang*

1423 Neurovascular invasion at the osteochondral junction and in osteophytes in osteoarthritis *S Suri, S E Gill, S Massena de Camin, D Wilson, D F McWilliams, D A Walsh*

1429 Gelatinase expression and proteolytic activity in giant-cell arteritis *M Segarra, A García-Martínez, M Sánchez, J Hernández-Rodríguez, E Lozano, J M Grau, M C Cid*

1436 The H63D variant in the *HFE* gene predisposes to arthralgia, chondrocalcinosis and osteoarthritis *B Z Alizadeh, O T Njajou, J M W Hazes, A Hofman, P E Slagboom, H A P Pols, C M van Duijn*

1443 Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial) *S M M Verstappen, J W G Jacobs, M J van der Veen, A H M Heurkens, Y Schenk, E J ter Borg, A A M Blaauw, J W J Bijlsma, on behalf of the Utrecht Rheumatoid Arthritis Cohort study group*

1450 Autoantibodies binding to citrullinated telopeptide of type II collagen and to cyclic citrullinated peptides predict synergistically the development of seropositive rheumatoid arthritis *M-K Koivula, M Heliövaara, J Ramberg, P Knekt, H Rissanen, T Palosuo, J Risteli*

1456 Predicting poor functional older adults with knee pain: prognostic value of generic indicators *C D Mallen, G Peat, E Thomas, R Lacey, P Croft*

1462 Low-dose glucocorticoid therapy decreases risk for treatment-limiting infusion reaction to infliximab in patients with rheumatoid arthritis *J Augustsson, S Eksborg, S Ernestam, E Gullström, R van Vollenhoven*

1467 Selective endothelin_A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease *R E Girgis, A E Frost, N S Hill, E M Horn, D Langleben, V V McLaughlin, R J Oudiz, I M Robbins, J R Seibold, S Shapiro, V F Tapson, R J Barst*

1473 The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice *W Kievit, J Fransen, A J M Oerlemans, H H Kuper, M A F J van der Laar, D J R A M de Rooij*



www.publicationethics.org.uk
This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

Ann Rheum Dis: first published as on 1 November 2007. Downloaded from <http://ard.bmj.com/> on 24 June 2019 by guest. Protected by copyright.

- C M A De Gendt, K H Ronday, T L Jansen, P C M van Oijen, H L M Brus, E M Adang, P L C M van Riel
- 1479 Performance of referral recommendations in patients with chronic back pain and suspected axial spondyloarthritis
H C Brandt, I Spiller, I-H Song, J L Vahldiek, M Rudwaleit, J Sieper
- 1485 Changes in priorities for improvement in patients with rheumatoid arthritis during 1 year of anti-tumour necrosis factor treatment
P M ten Klooster, M M Veehof, E Taal, P L C M van Riel, M A F J van de Laar
- 1491 QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries
T Sokka, H Kautiainen, S Toloza, H Mäkinen, S M M Verstappen, M L Hetland, A Naranjo, E Baecklund, G Herborn, R Rau, M Cazzato, L Gossec, V Skakic, F Gogus, S Sierakowski, B Bresnihan, P Taylor, C McClinton, T Pincus, for the QUEST-RA Group
- 1497 Opposing effects of the D70 mutation and the shared epitope in HLA-DR4 on disease activity and certain disease phenotypes in rheumatoid arthritis
N A Shadick, J E Heller, M E Weinblatt, N E Maher, J Cui, G Ginsburg, J Coblyn, R Anderson, D H Solomon, R Roubenoff, A Parker
- 1503 Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis
C Popa, F H J van den Hoogen, T R D J Radstake, M G Netea, A E Eijsbouts, M den Heijer, J W M van der Meer, P L C M van Riel, A F H Stalenhoef, P Barrera
- 1508 Bone mineral density in patients with recently diagnosed, active rheumatoid arthritis
M Güler-Yüksel, J Bijsterbosch, Y P M Goekoop-Ruiterman, J K de Vries-Bouwstra, H K Ronday, A J Peeters, J M de Jonge-Bok, F C Breedveld, B A C Dijkmans, C F Allaart, W F Lems
- 1513 Hand bone densitometry: a more sensitive standard for the assessment of early bone damage in rheumatoid arthritis
G Haugeberg, M J Green, P G Conaghan, M Quinn, R Wakefield, S M Proudman, S Stewart, E Hensor, P Emery
- 1518 Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment
M A J van Rossum, R M van Soesbergen, M Boers, A H Zwinderman, T J W Fiselier, M J A M Franssen, R ten Cate, L W A van Suijlekom-Smit, N M Wulffraat, W H J van Luijk, J C M Oostveen, W Kuis, Ben A C Dijkmans, on behalf of the Dutch Juvenile Idiopathic Arthritis Study group

- 1525 Macrophage migration inhibitory factor polymorphisms do not predict therapeutic response to glucocorticoids or to tumour necrosis factor α -neutralising treatments in rheumatoid arthritis
T R D J Radstake, J Fransen, E J M Toonen, M J H Coenen, A E Eijsbouts, R Donn, F H J van den Hoogen, P L C M van Riel

Articles carrying the



logo are available free online under the BMJ Journals unlocked scheme, see <http://ard.bmj.com/info/unlocked.dtl>

Concise reports

- 1531 The association of the PTPN22 620W polymorphism with Behçet's disease
V Baranathan, M R Stanford, R W Vaughan, E Kondeatis, E Graham, F Fortune, W Madanat, C Kanawati, M Ghabra, P I Murray, G R Wallace
- 1534 Limited correlation between the Health Assessment Questionnaire (HAQ) and EuroQol in rheumatoid arthritis: questionable validity of deriving quality adjusted life years from HAQ
D L Scott, B Khoshaba, E H Choy, G H Kingsley
- 1538 Does extremity-MRI improve erosion detection in severely damaged joints? A study of long-standing rheumatoid arthritis using three imaging modalities
J E Freeston, P G Conaghan, S Dass, E Vital, E M A Hensor, S P Stewart, P Emery

Letters

- 1541 Coexistent MEFV and CIAS1 mutations manifesting as familial Mediterranean fever plus deafness
D Singh-Grewal, J Chaitow, I Aksentijevich, J Christodoulou
- 1542 Metabolic syndrome in systemic lupus erythematosus: lower prevalence in Brazil than in the USA
G D Azevedo, R G N Gadelha, M J Vilar
- 1543 Incidence and predictors of severe extra-articular disease manifestations in an early rheumatoid arthritis inception cohort
C Turesson, K Eberhardt, L T H Jacobsson, E Lindqvist
- 1544 The use of the tumour necrosis factor antagonist infliximab in heart transplant recipients: two case reports
S Metyas, D La, D G Arkfeld
- 1545 Effective treatment of a colchicine-resistant familial Mediterranean fever patient with anakinra
L M Kuijk, A M A P Govers, W J D Hofhuis, J Frenkel
- 1547 Relationship between blood hydroxychloroquine and desethylchloroquine concentrations and cigarette smoking in treated patients with connective tissue diseases
G Leroux, N Costedoat-Chalumeau, J-S Hulot, Z Amoura, C Francès, G Aymard, P Lechat, J-C Piette

- 1548 Corrections